BioArctic AB (publ)
Buy by Alpha
Bioarctic is a Biotechnology research company with commercial approved Alzheimer medication LEQEMBI, and treatments for other neurodegenerative diseases. The company is a pioneer and global market leader for Alzheimer treatment.
The LEQEMBI sales are expected to turn BioArctic profitable in 2025. The fast growing license revenue complemented with (large) milestone payments result in a strong positive cash-flow. BioArctic is compounding on its technology with a portfolio of project and collaborations. As research company it invests heavily in R&D.
BioArctic is a volatile investment, with volatile earnings due to large milestones, currently valued at 25x PE. I think the share price has the potential to double in the longer term (3-5 years). This is a quality company to invest in that requires some risk tolerance. Major price action triggers can be expected in the short-term from new collaboration agreements, whereas bad news/volatility can create opportunities to increase the position.
- 350.00 +18.24% (30/10/2026)
30/10/2025| Analyses:13
1